Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy
Authors:
- 29 March 2018
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 139 (3) , 171-175
Abstract
The standard of care for upfront remission induction therapy for “fit” adults with de novo acute myeloid leukemia (AML) is continuous-infusion cytarabine with concurrent anthracycline (i.e., “7+3” regimen) [1]. Fourteen days after the initiation of chemotherapy, bone marrow is re-evaluated to identify patients who may benefit from immediate receipt of an additional cycle of remission induction chemotherapy. Current NCCN guidelines specify that a second cycle of induction chemotherapy should be administered prior to count recovery if (1) more than 5% of the cells in the day-14 bone marrow sample are morphologically consistent with myeloblasts and (2) the clinical status of the patient permits safe administration of cytotoxic therapy [2].Keywords
This publication has 15 references indexed in Scilit:
- Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemiaCritical Reviews in Oncology/Hematology, 2015
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2015
- Value of routine ‘day 14’ marrow exam in newly diagnosed AMLLeukemia, 2014
- Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseLeukemia, 2014
- Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?Current Hematologic Malignancy Reports, 2013
- Next‐generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3‐ITD or NPM1 mutationsGenes, Chromosomes and Cancer, 2012
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid LeukemiaAmerican Journal of Clinical Pathology, 2009
- Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemiaHaematologica, 2008
- Evaluation of complete disease remission in acute myeloid leukemiaCancer, 2006